Clinical Efficacy of Aspirin Combined with Rivaroxaban in Patients with Long-Term Implantation of Inferior Vena Cava Filter

Objective We sought to explore the clinical effectiveness of aspirin combined with rivaroxaban in patients with long-term inferior vena cava filters (IVCF). Methods 75 patients who had received long-term implanted IVCF in the Third People’s Hospital of Hefei and the First Hospital Affiliated with Anhui University of Traditional Chinese Medicine from August 2021 to December 2023 were selected and categorized into three groups: Group A (didn’t receive any oral treatment), B (received oral rivaroxaban postoperatively), and C received (aspirin + rivaroxaban, orally) of 25, 25, and 24 patients, respectively as one patient was excluded from group A, due to IVCF retrieval during treatment. All three groups were followed up at 1 month, 3 months, 6 months, and 12 months. Results Compared with group B, the recurrence and progression of DVT, thrombosis of IVCF, and score of Venous Clinical Severity Score (VCSS) at 12 months post-surgery were significantly higher in group A (P < 0.05). Regarding PE, neither cases nor symptoms were reported in all groups (P > 0.05). The incidence of bleeding in Group C was significantly higher than in Group B (P < 0.05); however, no statistically significant difference in bleeding was observed between Groups A and B (P > 0.05). Conclusion Compared to the absence of anticoagulant therapy, the administration of rivaroxaban significantly reduces complications and alleviates clinical symptoms in patients with long-term IVCF implantation. However, (aspirin + rivaroxaban) did not demonstrate any additional effect compared to rivaroxaban monotherapy, and it is linked to a higher risk of bleeding.